Tranexamic acid

Generic Name: Tranexamic acid

Brand Names: Cyklokapron, Lysteda

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₅NO_₂

CAS Number: 1197-18-8

Unique Ingredient Identifier: 6T84R30KC1

Background: Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication: Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.

Associated Conditions: Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)

Associated Therapies: -

Clinical Trials

Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA

Phase 3

Completed

Conditions: Blood Loss

Interventions: Drug: Tranexamic Acid

First Posted Date: 2013-06-19

Last Posted Date: 2014-12-03

Lead Sponsor: Hospital Universitario La Paz

Target Recruit Count: 79

Registration Number: NCT01881568

Locations: 🇪🇸
Hospital Universitario La Paz, Madrid, Spain

Tranexamic Acid During Cystectomy Trial (TACT)

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: Placebo
Drug: Tranexamic Acid

First Posted Date: 2013-06-05

Last Posted Date: 2022-10-04

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 354

Registration Number: NCT01869413

Locations: 🇨🇦
Northern Alberta Urology Centre, Edmonton, Alberta, Canada
🇨🇦
London Health Sciences Complex (LHSC), London, Ontario, Canada
🇨🇦
McGill University Health Centre (MUHC), Montréal, Quebec, Canada

and more 7 locations

Role of Topical Tranexamic Acid in Total Hip Arthroplasty

Phase 2

Terminated

Conditions: Post Operative Blood Loss

Interventions: Drug: Normal Saline Solution
Drug: Tranexamic Acid

First Posted Date: 2013-06-03

Last Posted Date: 2018-03-13

Lead Sponsor: Northwell Health

Target Recruit Count: 41

Registration Number: NCT01866943

Locations: 🇺🇸
North Shore Long Island Jewish Lenox Hill Hospital, New York, New York, United States

Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement

Not Applicable

Completed

Conditions: Primary Osteoarthritis of Knee Nos

Interventions: Drug: Physiologic saline
Drug: Tranexamic Acid

First Posted Date: 2013-05-09

Last Posted Date: 2013-12-13

Lead Sponsor: Mahidol University

Target Recruit Count: 152

Registration Number: NCT01850394

Locations: 🇹🇭
Ramathibodi Hospital, Bangkok, Thailand

Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding

Phase 4

Completed

Conditions: Heavy Menstrual Bleeding

Interventions: Drug: Tranexamic Acid

First Posted Date: 2013-05-03

Last Posted Date: 2018-10-24

Lead Sponsor: Nationwide Children's Hospital

Target Recruit Count: 32

Registration Number: NCT01846507

Locations: 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸
Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States
🇺🇸
Akron Children's Hospital, Akron, Ohio, United States

and more 2 locations

Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?

Phase 1

Completed

Conditions: Adolescent Idiopathic Scoliosis

Interventions: Drug: Placebo
Drug: Tranexamic Acid

First Posted Date: 2013-03-18

Last Posted Date: 2019-02-20

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 120

Registration Number: NCT01813058

Locations: 🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States

The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery

Phase 2

Completed

Conditions: Curvature of Spine

Interventions: Drug: Tranexamic Acid

First Posted Date: 2012-11-20

Last Posted Date: 2021-01-26

Lead Sponsor: Northwestern University

Target Recruit Count: 61

Registration Number: NCT01728636

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Topical Application of Tranexamic Acid and Postoperative Blood Loss in Femoral Neck Fractures

Phase 3

Terminated

Conditions: Femoral Neck Fracture

Interventions: Other: placebo
Drug: Tranexamic Acid

First Posted Date: 2012-11-16

Last Posted Date: 2018-11-30

Lead Sponsor: Dr. Jeff Yach

Target Recruit Count: 15

Registration Number: NCT01727843

Locations: 🇨🇦
Queen's Univeristy, KGH, Kingston, Ontario, Canada

Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?

Phase 4

Completed

Conditions: Hip Fracture

Interventions: Drug: placebo
Drug: tranexamic acid

First Posted Date: 2012-10-25

Last Posted Date: 2018-11-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 138

Registration Number: NCT01714336

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

Phase 2

Completed

Conditions: Stroke
Intracerebral Haemorrhage

Interventions: Drug: Placebo
Drug: Tranexamic Acid

First Posted Date: 2012-10-08

Last Posted Date: 2020-02-26

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 100

Registration Number: NCT01702636

Locations: 🇦🇺
John Hunter Hospital, Newcastle, New South Wales, Australia
🇦🇺
Frankston Hospital, Frankston, Victoria, Australia
🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy